This review evaluated topically applied capsaicin for the treatment of chronic neuropathic and musculoskeletal pain. The authors concluded that capsaicin had a poor to moderate efficacy, but may be useful in people unresponsive to, or intolerant of other treatments. Apparent differences across the included studies and the lack of an analysis of data for this subgroup suggest that the conclusions may not be reliable.
Results of the review
Sixteen studies (n=1,556) were included in the review.
Four studies scored 4 out of 5 on the quality assessment, ten scored 3, and two scored 2. On the 16-point validity assessment, the scores ranged from 9 to 14.
Efficacy.
Based on 313 patients in 4 studies, capsaicin resulted in a statistically significant improvement in neuropathic pain at 4 weeks (RR 1.4, 95% CI: 1.1, 1.7); the corresponding NNT was 6.4 (95% CI: 3.8, 21). No results for the assessment of heterogeneity were presented. Capsaicin also resulted in a statistically significant improvement in neuropathic pain at 8 weeks (RR 1.4, 95% CI: 1.2, 1.7) and a corresponding NNT of 5.7 (95% CI: 4.0, 10), based on 656 patients in 6 studies. There was evidence of statistical heterogeneity for the comparison at 8 weeks (P=0.02; I2=62.5%).
Based on 368 patients in 3 studies, capsaicin resulted in a statistically significant improvement in musculoskeletal pain at 4 weeks (RR 1.5, 95% CI: 1.1, 2.07) and a corresponding NNT of 8.1 (95% CI: 4.6, 34, P=0.01). There was no evidence of statistical heterogeneity (P=0.36; I2=2.5%). Subgroup analyses showed no significant effect of trial size or outcome measured.
Adverse events.
Based on 300 patients in 4 studies, capsaicin caused a statistically significant higher rate of local adverse events at 8 weeks than placebo when used for neuropathic pain (RR 3.2, 95% CI: 2.2, 4.6; NNH 2.5, 95% CI: 2.0, 3.3).
Based on 190 patients in 3 studies, capsaicin caused a statistically significant higher rate of local adverse events at 4 weeks than placebo when used for musculoskeletal pain (RR 5.0, 95% CI: 2.6, 9.6; NNH 2.6, 95% CI: 2.06, 3.6).
Withdrawals due to adverse events were significantly higher with capsaicin than placebo when used for neuropathic pain (5 studies with 503 patients; RR 5.5, 95% CI: 2.6, 12; NNH 7.5, 95% CI: 5.5, 12) and for musculoskeletal pain (4 studies with 398 patients; RR 2.5, 95% CI: 1.1, 5.6; NNH 16, 95% CI: 9.1, 63).
